Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Employees

122

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/09/26	HK$3.250	-0.91%	606,500
16/09/26	HK$3.280	-2.09%	764,500
15/09/26	HK$3.350	-2.19%	530,500
14/09/26	HK$3.425	+2.54%	698,500
11/09/26	HK$3.340	-3.19%	1,492,500

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.804CNY

Average target price

4.150CNY

Spread / Average Target

+47.98%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Hong Kong S.E. 06:55:11 17/09/2026 +04			5-day change	1st Jan Change
3.250 ^HKD	-0.91%		-5.94%	-14.38%

08-25	Antengene Corporation Limited Receives HREC Approval In Australia For Phase I ATTRACT Study Of ATG-201 In B Cell-Related Autoimmune Diseases	CI
08-25	Antengene's Autoimmune Disease Drug Candidate Approved for Phase I Trial in Australia	MT

Market Cap	1.9B 2.23B 284M 246M 233M 211M 396M 27.24B 398M 2.78B 1.07B 13.82B 1.07B 1.04B 44.05B	P/E 2026 *	5.29x	P/E 2027 *	-21.6x
Enterprise Value	1.9B 2.23B 284M 246M 233M 211M 396M 27.24B 398M 2.78B 1.07B 13.82B 1.07B 1.04B 44.05B	EV / Sales 2026 *	2.29x	EV / Sales 2027 *	5.64x
Free-Float	63.11%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	6996	Delayed
Tradegate	722	Real-time
Börse Stuttgart	722	Delayed
Deutsche Boerse AG	722	Delayed

08-25	Antengene Corporation Limited Receives HREC Approval In Australia For Phase I ATTRACT Study Of ATG-201 In B Cell-Related Autoimmune Diseases	CI
08-25	Antengene's Autoimmune Disease Drug Candidate Approved for Phase I Trial in Australia	MT
08-21	Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-19	Antengene Presents Key R&D Highlights Including Atg-022 Clinical Data, Antengager and Trigager Tce Platforms, and Atg-207 Bifunctional Fusion Protein	CI
07-31	Antengene's CFO Steps Down; Chief Business Officer Named	MT
07-31	Antengene Corporation Limited Announces Management Changes, Effective August 1, 2026	CI
07-31	Antengene Corporation Limited Announces Resignation of Donald Andrew Lung as Chief Financial Officer, Effective August 1, 2026	CI
07-28	Antengene Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026	CI
07-13	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT
07-10	Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target	MT
07-09	Antengene Corporation Limited commences an Equity Buyback Plan for 67,924,413 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2026.	CI
06-25	Antengene Plans Up to HK$50 Million Share Buyback	MT
06-22	Antengene Corporation Limited And K2 Therapeutics Enter Exclusive License Agreement For ATG-106 And Option For Undisclosed Bispecific TCE	CI

Antengene Corporation Limited Stock

Stocks

6996

KYG039571008

Biotechnology & Medical Research

Valuation: Antengene Corporation Limited

Chart: Antengene Corporation Limited

Latest news: Antengene Corporation Limited

Analysts' recommendations: Antengene Corporation Limited

Press Releases: Antengene Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: Antengene Corporation Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

09-14	Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy	PR
08-25	Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases	PR
08-24	Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D	PR
08-19	Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit	PR
07-20	Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026	PR

1 day	-1.07%
1 week	-5.94%
Current month	-11.70%
1 month	-20.85%
3 months	-3.71%
6 months	-22.37%
Current year	-14.38%

1 week	3.16	3.58
1 month	3.16	4.24
Current year	2.76	6.28
1 year	2.76	7.38
3 years	0.5	8.16
5 years	0.5	13.06
10 years	0.5	22.5

Manager	Title	Age	Since
Jian Ming Mei CEO	Chief Executive Officer	60	28/08/2018
Bing Hou CTO	Chief Tech/Sci/R&D Officer	42	20/05/2026
Godfrey Guo CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jian Ming Mei CHM	Chairman	60	28/08/2018
Jing Qian BRD	Director/Board Member	51	09/11/2020
Rafael Fonseca BRD	Director/Board Member	59	14/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/04/26	Jian Ming Mei	Other	Chief Executive Officer	600,000	0.0883%
24/03/26	Jian Ming Mei	Other	Chief Executive Officer	100,000	0.0147%
24/03/26	Donald Lung	Other	Chief Financial Officer	235,000	0.0346%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANTENGENE CORPORATION LIMITED	-0.91%	-5.94%	-51.49%	+197.71%	290M
WUXI APPTEC CO., LTD.	+0.66%	+1.83%	+47.32%	+97.63%	69.18B
ARGENX SE	-1.19%	-1.92%	+34.57%	+73.08%	62B
INSMED INCORPORATED	+2.22%	-4.83%	-15.32%	+360.65%	26.19B
WUXI BIOLOGICS (CAYMAN) INC.	+0.92%	+6.00%	+28.38%	+15.48%	25.75B
BIONTECH SE	-0.89%	-2.34%	-3.46%	-15.24%	24.29B
GENMAB A/S	+2.84%	+3.61%	+24.60%	-17.13%	19.84B
PHARMAESSENTIA CORPORATION	0.00%	-10.41%	+171.96%	+298.75%	15.65B
EXELIXIS, INC.	-0.21%	-2.66%	+45.07%	+160.34%	14.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.69%	-2.19%	-9.29%	+459.04%	14.09B
Average	+0.39%	-2.19%	+27.23%	+163.03%	27.14B
Weighted average by Cap.	+0.34%	-1.25%	+34.39%	+124.85%

	2026 *	2027 *
Net sales	830M 971M 124M 107M 101M 92.05M 173M 11.88B 174M 1.21B 468M 6.02B 465M 455M 19.2B	338M 395M 50.35M 43.63M 41.24M 37.44M 70.17M 4.83B 70.59M 492M 190M 2.45B 189M 185M 7.81B
Net income	333M 390M 49.68M 43.06M 40.69M 36.94M 69.24M 4.77B 69.66M 486M 188M 2.42B 187M 182M 7.71B	-84.79M -99.17M -12.64M -10.95M -10.35M -9.4M -17.62M -1.21B -17.72M -124M -47.76M -615M -47.49M -46.43M -1.96B
Net Debt	-	-